WEO Media vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Dental marketing agency providing websites, SEO, PPC, and patient communication for dental practices in the US and Canada. Beaverton OR; founded 2009;
About
WEO Media is a Beaverton, Oregon-based dental-specific marketing agency and technology company that provides website design, search engine optimization, pay-per-click advertising, online reputation management, and patient communication tools to dental practices across the United States and Canada. Founded in 2009, WEO Media built its business around the unique marketing needs of independent dental practices and DSO-affiliated offices, which differ significantly from general small business marketing in their emphasis on local search visibility, treatment-specific landing pages, patient reviews, and HIPAA-compliant communication. The company combines managed digital marketing services with proprietary technology tools for patient communication and review generation, offering dental practices a full-service growth marketing partner.\n\nWEO Media's website platform is purpose-built for dental practices, with built-in features for treatment page templates, appointment request forms, before-and-after gallery management, and ADA accessibility compliance. The company's SEO methodology focuses on local search dominance—ensuring that each dental practice ranks prominently for high-intent searches like "dentist near me," "dental implants [city]," and "emergency dentist [neighborhood]"—which drives the majority of new patient acquisition for most dental offices. WEO Media manages Google Business Profiles, local citation building, and online review acquisition campaigns as integrated components of its local SEO service.\n\nWEO Media targets independent dental practices and small group practices that want to outsource their digital marketing to a specialist with deep dental industry knowledge rather than working with a general digital marketing agency that lacks familiarity with dental treatment marketing, HIPAA compliance requirements, and the competitive dynamics of local dental markets. The company competes with ProSites, TNT Dental, and PatientSites in the dental marketing agency space, as well as with in-house marketing capabilities at larger DSOs. WEO Media differentiates on its combination of managed services and proprietary technology and its long track record in the dental market.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.